Teplizumab and immune modulation
Review what immune treatment can preserve or delay, how the 2026 indications differ, and why disease modification is not a universal cure.
By The Diabetes Guide editorial project · Updated 30 Sept 2026
On this page
Teplizumab calms the immune reaction that harms beta cells. It slows Type 1 in selected people; it does not build new cells.
Step 1: How it works
It targets CD3 on T cells to change their behavior.
For example: A referee who tells the players to calm down.
Step 2: Who it is for
In the US it is approved for certain Stage 2 people, and for some recently diagnosed young people.
For example: A seat belt for particular roads only.
Step 3: What it does not do
It does not remove autoimmunity or the need for insulin in everyone.
For example: A brake slows a car; it does not turn the engine off forever.
Remember: Check the current label with a specialist.
The full story
Want more? Below is the detailed version with the real science words. It is fine to skip it.
Changing the immune process
Teplizumab targets CD3, a component of T-cell signaling. Its purpose is to modify immune activity, not manufacture new beta cells. The original TN-10 trial studied 76 high-risk participants and supported delay of clinical Type 1 in a selected population. 1
The 2026 US distinction
The current label includes Stage 2 delay of Stage 3 for eligible adults and children aged at least one year, and an accelerated indication for slowing secretion decline in selected newly diagnosed Stage 3 patients aged 8–17. Eligibility, testing, safety precautions and regimen differ by indication; use the current label with a specialist. 2
Why the endpoint matters
C-peptide preservation reflects endogenous secretion. It is meaningful but not identical to permanent insulin independence, freedom from complications or elimination of autoimmunity. The Stage 3 accelerated approval explicitly depends on a surrogate endpoint. 3
Immune tolerance, antigen-specific approaches and precision treatment are active research concepts. None justifies suggesting that all Type 1 can now be prevented.
Trace the evidence
Sources and further reading
1.Drug Trials Snapshot: Tzield original approval (opens in a new tab)
US Food and Drug Administration · 2022 · Randomized trial
Who was studied, limits and source check
Population: High-risk relatives with presymptomatic T1D
Sample: 76 participants in TN-10
Limitations: Original evidence concerns delay of Stage 3, not prevention for everyone; see the current label for updated eligibility.
Source checked 2026-09-30. See the original publication for full methods.
2.Tzield prescribing information, revised June 2026 (opens in a new tab)
US Food and Drug Administration · 2026 · Regulatory
Who was studied, limits and source check
Limitations: US label. Age and staging criteria differ between indications; specialist evaluation and infection precautions are required.
Source checked 2026-09-30. See the original publication for full methods.
3.FDA accelerated approval: teplizumab in selected recently diagnosed pediatric Stage 3 T1D (opens in a new tab)
US Food and Drug Administration · 2026 · Regulatory
Who was studied, limits and source check
Population: Children aged 8–17 recently diagnosed with Stage 3 T1D
Sample: PROTECT: 328 participants
Limitations: June 12 accelerated approval based on C-peptide preservation, a surrogate. Confirmatory clinical benefit and label conditions matter.
Source checked 2026-09-30. See the original publication for full methods.
Source checking is an editorial literature check, not independent medical review. This page is for learning. It cannot diagnose you or make a treatment plan. Evidence labels describe the cited claims, not the whole topic.
What does “Strong Evidence” mean?
Many good studies agree, with a few limits. Like a big taste test where almost everyone picked the same flavor.
Keep reading
The body
The one-page mental model
Diabetes means there is too much sugar in the blood for too long, because the body does not have enough insulin or cannot use it well.
Type 1
Type 1 diabetes: the complete journey
Type 1 diabetes is usually an autoimmune condition. The body’s defence system harms the beta cells, so less and less insulin is made.
Type 2
Type 2 diabetes: how the system changes
Type 2 diabetes happens when the body’s need for insulin grows and the pancreas cannot keep up, so sugar slowly rises.